Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision ...

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

Age-Related Macular Degeneration Market Epidemiology Report 2025-2035: Drugs Pipeline, Therapies, and Forecast The report provides a detail ...

A large, prospective study implicates high levels of interleukin 6 with severity of diabetic retinopathy and shows it may be ...

Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA ...

Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to ...

Meredith R. Klifto, MD, is an assistant professor of ophthalmology at the University of North Carolina School of Medicine, ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to ...

The prevalence and incidence of DRD has increased in recent years, while the incidence of VTDR, DME, and PDR has improved since 2000.

Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and ...

Researchers in a new study learned that consuming this specific type of coffee may substantially increase a person’s risk of ...

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related ...